SYTL2 promotes metastasis of prostate cancer cells by enhancing FSCN1-mediated pseudopodia formation and invasion

Metastatic prostate cancer (mPCa) has a poor prognosis with limited treatment options. The high mobility of tumor cells is the key driving characteristic of metastasis. However, the mechanism is complex and far from clarified in PCa. Therefore, it is essential to explore the mechanism of metastasis...

Full description

Saved in:
Bibliographic Details
Published inJournal of translational medicine Vol. 21; no. 1; pp. 303 - 15
Main Authors Li, Zean, Tao, Yiran, Gao, Ze, Peng, Shirong, Lai, Yiming, Li, Kaiwen, Chen, Xu, Huang, Hai
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 05.05.2023
BioMed Central
BMC
Subjects
Actin
Antibodies
Carrier Proteins - genetics
Cell culture
Cell Line, Tumor
Cell Movement - genetics
Cytoskeleton
Data analysis
Diagnosis
FSCN1
Genomes
Health aspects
Humans
Lymph nodes
Lymphatic Metastasis
Male
Medical prognosis
Membrane Proteins - genetics
Metastases
Metastasis
Microfilament Proteins - genetics
MicroRNAs - genetics
Mobility
Paraffin
Prognosis
Prostate cancer
Prostatic Neoplasms - genetics
Prostatic Neoplasms - pathology
Proteasomes
Protein binding
Proteins
Pseudopodia
Pseudopodia - metabolism
Risk factors
Survival analysis
Synaptotagmin
SYTL2
Transcriptomes
Tumor cells
China
United States > US
Japan
FSCN1
Pseudopodia
Metastasis
Prostate cancer
SYTL2
Online AccessGet full text

Cover

Abstract Metastatic prostate cancer (mPCa) has a poor prognosis with limited treatment options. The high mobility of tumor cells is the key driving characteristic of metastasis. However, the mechanism is complex and far from clarified in PCa. Therefore, it is essential to explore the mechanism of metastasis and discover an intrinsic biomarker for mPCa. Transcriptome sequencing data and clinicopathologic features of PCa from multifarious public databases were used to identify novel metastatic genes in PCa. The PCa tissue cohort containing 102 formalin-fixed paraffin-embedded (FFPE) samples was used to evaluate the clinicopathologic features of synaptotagmin-like 2 (SYTL2) in PCa. The function of SYTL2 was investigated by migration and invasion assays and a 3D migration model in vitro and a popliteal lymph node metastasis model in vivo. We performed coimmunoprecipitation and protein stability assays to clarify the mechanism of SYTL2. We discovered a pseudopodia regulator, SYTL2, which correlated with a higher Gleason score, worse prognosis and higher risk of metastasis. Functional experiments revealed that SYTL2 promoted migration, invasion and lymph node metastasis by increasing pseudopodia formation in vitro and in vivo. Furthermore, SYTL2 induced pseudopodia formation by enhancing the stability of fascin actin-bundling protein 1 (FSCN1) by binding and inhibiting the proteasome degradation pathway. Targeting FSCN1 enabled rescue and reversal of the oncogenic effect of SYTL2. Overall, our study established an FSCN1-dependent mechanism by which SYTL2 regulates the mobility of PCa cells. We also found that the SYTL2-FSCN1-pseudopodia axis may serve as a pharmacological and novel target for treating mPCa.
AbstractList Abstract Background Metastatic prostate cancer (mPCa) has a poor prognosis with limited treatment options. The high mobility of tumor cells is the key driving characteristic of metastasis. However, the mechanism is complex and far from clarified in PCa. Therefore, it is essential to explore the mechanism of metastasis and discover an intrinsic biomarker for mPCa. Methods Transcriptome sequencing data and clinicopathologic features of PCa from multifarious public databases were used to identify novel metastatic genes in PCa. The PCa tissue cohort containing 102 formalin-fixed paraffin-embedded (FFPE) samples was used to evaluate the clinicopathologic features of synaptotagmin-like 2 (SYTL2) in PCa. The function of SYTL2 was investigated by migration and invasion assays and a 3D migration model in vitro and a popliteal lymph node metastasis model in vivo. We performed coimmunoprecipitation and protein stability assays to clarify the mechanism of SYTL2. Results We discovered a pseudopodia regulator, SYTL2, which correlated with a higher Gleason score, worse prognosis and higher risk of metastasis. Functional experiments revealed that SYTL2 promoted migration, invasion and lymph node metastasis by increasing pseudopodia formation in vitro and in vivo. Furthermore, SYTL2 induced pseudopodia formation by enhancing the stability of fascin actin-bundling protein 1 (FSCN1) by binding and inhibiting the proteasome degradation pathway. Targeting FSCN1 enabled rescue and reversal of the oncogenic effect of SYTL2. Conclusions Overall, our study established an FSCN1-dependent mechanism by which SYTL2 regulates the mobility of PCa cells. We also found that the SYTL2-FSCN1-pseudopodia axis may serve as a pharmacological and novel target for treating mPCa.
Background Metastatic prostate cancer (mPCa) has a poor prognosis with limited treatment options. The high mobility of tumor cells is the key driving characteristic of metastasis. However, the mechanism is complex and far from clarified in PCa. Therefore, it is essential to explore the mechanism of metastasis and discover an intrinsic biomarker for mPCa. Methods Transcriptome sequencing data and clinicopathologic features of PCa from multifarious public databases were used to identify novel metastatic genes in PCa. The PCa tissue cohort containing 102 formalin-fixed paraffin-embedded (FFPE) samples was used to evaluate the clinicopathologic features of synaptotagmin-like 2 (SYTL2) in PCa. The function of SYTL2 was investigated by migration and invasion assays and a 3D migration model in vitro and a popliteal lymph node metastasis model in vivo. We performed coimmunoprecipitation and protein stability assays to clarify the mechanism of SYTL2. Results We discovered a pseudopodia regulator, SYTL2, which correlated with a higher Gleason score, worse prognosis and higher risk of metastasis. Functional experiments revealed that SYTL2 promoted migration, invasion and lymph node metastasis by increasing pseudopodia formation in vitro and in vivo. Furthermore, SYTL2 induced pseudopodia formation by enhancing the stability of fascin actin-bundling protein 1 (FSCN1) by binding and inhibiting the proteasome degradation pathway. Targeting FSCN1 enabled rescue and reversal of the oncogenic effect of SYTL2. Conclusions Overall, our study established an FSCN1-dependent mechanism by which SYTL2 regulates the mobility of PCa cells. We also found that the SYTL2-FSCN1-pseudopodia axis may serve as a pharmacological and novel target for treating mPCa. Keywords: SYTL2, Pseudopodia, Prostate cancer, Metastasis, FSCN1
Metastatic prostate cancer (mPCa) has a poor prognosis with limited treatment options. The high mobility of tumor cells is the key driving characteristic of metastasis. However, the mechanism is complex and far from clarified in PCa. Therefore, it is essential to explore the mechanism of metastasis and discover an intrinsic biomarker for mPCa.BACKGROUNDMetastatic prostate cancer (mPCa) has a poor prognosis with limited treatment options. The high mobility of tumor cells is the key driving characteristic of metastasis. However, the mechanism is complex and far from clarified in PCa. Therefore, it is essential to explore the mechanism of metastasis and discover an intrinsic biomarker for mPCa.Transcriptome sequencing data and clinicopathologic features of PCa from multifarious public databases were used to identify novel metastatic genes in PCa. The PCa tissue cohort containing 102 formalin-fixed paraffin-embedded (FFPE) samples was used to evaluate the clinicopathologic features of synaptotagmin-like 2 (SYTL2) in PCa. The function of SYTL2 was investigated by migration and invasion assays and a 3D migration model in vitro and a popliteal lymph node metastasis model in vivo. We performed coimmunoprecipitation and protein stability assays to clarify the mechanism of SYTL2.METHODSTranscriptome sequencing data and clinicopathologic features of PCa from multifarious public databases were used to identify novel metastatic genes in PCa. The PCa tissue cohort containing 102 formalin-fixed paraffin-embedded (FFPE) samples was used to evaluate the clinicopathologic features of synaptotagmin-like 2 (SYTL2) in PCa. The function of SYTL2 was investigated by migration and invasion assays and a 3D migration model in vitro and a popliteal lymph node metastasis model in vivo. We performed coimmunoprecipitation and protein stability assays to clarify the mechanism of SYTL2.We discovered a pseudopodia regulator, SYTL2, which correlated with a higher Gleason score, worse prognosis and higher risk of metastasis. Functional experiments revealed that SYTL2 promoted migration, invasion and lymph node metastasis by increasing pseudopodia formation in vitro and in vivo. Furthermore, SYTL2 induced pseudopodia formation by enhancing the stability of fascin actin-bundling protein 1 (FSCN1) by binding and inhibiting the proteasome degradation pathway. Targeting FSCN1 enabled rescue and reversal of the oncogenic effect of SYTL2.RESULTSWe discovered a pseudopodia regulator, SYTL2, which correlated with a higher Gleason score, worse prognosis and higher risk of metastasis. Functional experiments revealed that SYTL2 promoted migration, invasion and lymph node metastasis by increasing pseudopodia formation in vitro and in vivo. Furthermore, SYTL2 induced pseudopodia formation by enhancing the stability of fascin actin-bundling protein 1 (FSCN1) by binding and inhibiting the proteasome degradation pathway. Targeting FSCN1 enabled rescue and reversal of the oncogenic effect of SYTL2.Overall, our study established an FSCN1-dependent mechanism by which SYTL2 regulates the mobility of PCa cells. We also found that the SYTL2-FSCN1-pseudopodia axis may serve as a pharmacological and novel target for treating mPCa.CONCLUSIONSOverall, our study established an FSCN1-dependent mechanism by which SYTL2 regulates the mobility of PCa cells. We also found that the SYTL2-FSCN1-pseudopodia axis may serve as a pharmacological and novel target for treating mPCa.
Metastatic prostate cancer (mPCa) has a poor prognosis with limited treatment options. The high mobility of tumor cells is the key driving characteristic of metastasis. However, the mechanism is complex and far from clarified in PCa. Therefore, it is essential to explore the mechanism of metastasis and discover an intrinsic biomarker for mPCa. Transcriptome sequencing data and clinicopathologic features of PCa from multifarious public databases were used to identify novel metastatic genes in PCa. The PCa tissue cohort containing 102 formalin-fixed paraffin-embedded (FFPE) samples was used to evaluate the clinicopathologic features of synaptotagmin-like 2 (SYTL2) in PCa. The function of SYTL2 was investigated by migration and invasion assays and a 3D migration model in vitro and a popliteal lymph node metastasis model in vivo. We performed coimmunoprecipitation and protein stability assays to clarify the mechanism of SYTL2. We discovered a pseudopodia regulator, SYTL2, which correlated with a higher Gleason score, worse prognosis and higher risk of metastasis. Functional experiments revealed that SYTL2 promoted migration, invasion and lymph node metastasis by increasing pseudopodia formation in vitro and in vivo. Furthermore, SYTL2 induced pseudopodia formation by enhancing the stability of fascin actin-bundling protein 1 (FSCN1) by binding and inhibiting the proteasome degradation pathway. Targeting FSCN1 enabled rescue and reversal of the oncogenic effect of SYTL2. Overall, our study established an FSCN1-dependent mechanism by which SYTL2 regulates the mobility of PCa cells. We also found that the SYTL2-FSCN1-pseudopodia axis may serve as a pharmacological and novel target for treating mPCa.
BackgroundMetastatic prostate cancer (mPCa) has a poor prognosis with limited treatment options. The high mobility of tumor cells is the key driving characteristic of metastasis. However, the mechanism is complex and far from clarified in PCa. Therefore, it is essential to explore the mechanism of metastasis and discover an intrinsic biomarker for mPCa.MethodsTranscriptome sequencing data and clinicopathologic features of PCa from multifarious public databases were used to identify novel metastatic genes in PCa. The PCa tissue cohort containing 102 formalin-fixed paraffin-embedded (FFPE) samples was used to evaluate the clinicopathologic features of synaptotagmin-like 2 (SYTL2) in PCa. The function of SYTL2 was investigated by migration and invasion assays and a 3D migration model in vitro and a popliteal lymph node metastasis model in vivo. We performed coimmunoprecipitation and protein stability assays to clarify the mechanism of SYTL2.ResultsWe discovered a pseudopodia regulator, SYTL2, which correlated with a higher Gleason score, worse prognosis and higher risk of metastasis. Functional experiments revealed that SYTL2 promoted migration, invasion and lymph node metastasis by increasing pseudopodia formation in vitro and in vivo. Furthermore, SYTL2 induced pseudopodia formation by enhancing the stability of fascin actin-bundling protein 1 (FSCN1) by binding and inhibiting the proteasome degradation pathway. Targeting FSCN1 enabled rescue and reversal of the oncogenic effect of SYTL2.ConclusionsOverall, our study established an FSCN1-dependent mechanism by which SYTL2 regulates the mobility of PCa cells. We also found that the SYTL2-FSCN1-pseudopodia axis may serve as a pharmacological and novel target for treating mPCa.
Metastatic prostate cancer (mPCa) has a poor prognosis with limited treatment options. The high mobility of tumor cells is the key driving characteristic of metastasis. However, the mechanism is complex and far from clarified in PCa. Therefore, it is essential to explore the mechanism of metastasis and discover an intrinsic biomarker for mPCa. Transcriptome sequencing data and clinicopathologic features of PCa from multifarious public databases were used to identify novel metastatic genes in PCa. The PCa tissue cohort containing 102 formalin-fixed paraffin-embedded (FFPE) samples was used to evaluate the clinicopathologic features of synaptotagmin-like 2 (SYTL2) in PCa. The function of SYTL2 was investigated by migration and invasion assays and a 3D migration model in vitro and a popliteal lymph node metastasis model in vivo. We performed coimmunoprecipitation and protein stability assays to clarify the mechanism of SYTL2. We discovered a pseudopodia regulator, SYTL2, which correlated with a higher Gleason score, worse prognosis and higher risk of metastasis. Functional experiments revealed that SYTL2 promoted migration, invasion and lymph node metastasis by increasing pseudopodia formation in vitro and in vivo. Furthermore, SYTL2 induced pseudopodia formation by enhancing the stability of fascin actin-bundling protein 1 (FSCN1) by binding and inhibiting the proteasome degradation pathway. Targeting FSCN1 enabled rescue and reversal of the oncogenic effect of SYTL2. Overall, our study established an FSCN1-dependent mechanism by which SYTL2 regulates the mobility of PCa cells. We also found that the SYTL2-FSCN1-pseudopodia axis may serve as a pharmacological and novel target for treating mPCa.
ArticleNumber 303
Audience Academic
Author Li, Kaiwen
Lai, Yiming
Li, Zean
Huang, Hai
Peng, Shirong
Gao, Ze
Tao, Yiran
Chen, Xu
Author_xml – sequence: 1
  givenname: Zean
  surname: Li
  fullname: Li, Zean
– sequence: 2
  givenname: Yiran
  surname: Tao
  fullname: Tao, Yiran
– sequence: 3
  givenname: Ze
  surname: Gao
  fullname: Gao, Ze
– sequence: 4
  givenname: Shirong
  surname: Peng
  fullname: Peng, Shirong
– sequence: 5
  givenname: Yiming
  surname: Lai
  fullname: Lai, Yiming
– sequence: 6
  givenname: Kaiwen
  surname: Li
  fullname: Li, Kaiwen
– sequence: 7
  givenname: Xu
  surname: Chen
  fullname: Chen, Xu
– sequence: 8
  givenname: Hai
  orcidid: 0000-0002-2013-073X
  surname: Huang
  fullname: Huang, Hai
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37147713$$D View this record in MEDLINE/PubMed
BookMark eNp9kktv3CAUha0qVfNo_0AXFVI33TgFGzCsqmiUtJFG7SLpoiuEeUwY2TABT6T5970zk6aZqKqMDFy-e-yDzml1FFN0VfWe4HNCBP9cSCN5V-OmrTEllNebV9UJoZ2smej40bP1cXVayhLjhjIq31THbQdHHWlPqvubX7fzBq1yGtPkChrdpAuMUFDy2zJsJoeMjsZlZNwwFNRvkIt3UAlxga5uZt9JPTobgLNoVdzaplWCLfIpj3oKKSIdLQrxAWRTfFu99noo7t3jfFb9vLq8nX2r5z--Xs8u5rVhnE61Z31vW8uY5UzAC2Pc9cK2xAjBpfau9Zwxx5gxrZYtdx33hHjtod301LRn1fVe1ya9VKscRp03KumgdoWUF0rnKZjBKS-95bQx2BtCPTV9K4WRfSe61mpDBGh92Wut1j1YNS5OWQ8HoocnMdypRXpQBBNOwA8ofHpUyOl-7cqkxlC216mjS-uiGkGwJB2XDaAfX6DLtM4R7mpLMc6bhvG_1EKDgxB9gg-brai66KhoBMVSAnX-Dwoe68ZgIE4-QP2g4cNzp08W_yQGgGYPGMhGyc4_IQSrbSzVPpYKYql2sVQbaBIvmkyYdtGA3wnD_1p_Aw7g57w
CitedBy_id crossref_primary_10_1016_j_bbadis_2023_166916
crossref_primary_10_3389_fcell_2024_1430386
crossref_primary_10_1021_acsbiomaterials_4c00345
Cites_doi 10.1097/CM9.0000000000002108
10.1038/nm.3394
10.1038/nm.3391
10.1002/ctm2.191
10.1111/cas.14014
10.1016/j.canlet.2012.09.021
10.7150/ijbs.56694
10.1016/j.cell.2016.11.037
10.1038/s41467-020-14657-7
10.1016/j.str.2008.07.015
10.1111/cpr.12994
10.7150/thno.28898
10.1161/ATVBAHA.121.316113
10.1038/s41598-018-24256-8
10.3390/cancers11040434
10.1016/j.cub.2013.06.013
10.1083/jcb.202006196
10.1016/j.urolonc.2018.05.008
10.3892/or.2012.2191
10.1248/bpb.32.1101
10.1091/mbc.e06-10-0914
10.1038/nature14347
10.1038/195045a0
10.1006/bbrc.2001.4512
10.1016/j.cclet.2021.11.078
10.1038/nrc2618
10.1111/j.1600-0854.2008.00714.x
10.1186/s12943-018-0825-x
10.1016/j.bbrc.2015.03.099
10.3322/caac.21708
10.1038/s41586-020-2135-x
10.4155/fmc-2019-0223
10.1038/s41401-020-0399-1
10.1091/mbc.e12-02-0104
10.3892/or.2016.4835
10.1038/onc.2015.444
10.1038/cr.2012.10
10.1016/j.apsb.2015.07.005
10.21203/rs.3.rs-1800606/v1
10.1002/cac2.12284
ContentType Journal Article
Copyright 2023. The Author(s).
COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2023
Copyright_xml – notice: 2023. The Author(s).
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2023
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12967-023-04146-y
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ (Directory of Open Access Journals)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic

Publicly Available Content Database
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central Database Suite (ProQuest)
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1479-5876
EndPage 15
ExternalDocumentID oai_doaj_org_article_f9fd642c0fc14f4cb398c9b7873dac18
PMC10161564
A748284099
37147713
10_1186_s12967_023_04146_y
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations China
United States--US
Japan
GeographicLocations_xml – name: China
– name: United States--US
– name: Japan
GrantInformation_xml – fundername: ;
  grantid: 81974395; 82173036; 82072827; 82273421
GroupedDBID ---
0R~
29L
2WC
53G
5VS
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
-A0
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
7T5
7XB
8FK
AZQEC
DWQXO
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c564t-f5bbd3d55d6585d60007b8d31c8869afe3f655e55cc3a936e76f11fafc56cb4c3
IEDL.DBID M48
ISSN 1479-5876
IngestDate Wed Aug 27 01:30:57 EDT 2025
Thu Aug 21 18:37:20 EDT 2025
Fri Jul 11 05:23:19 EDT 2025
Fri Jul 25 05:30:41 EDT 2025
Tue Jun 17 21:43:41 EDT 2025
Tue Jun 10 20:45:59 EDT 2025
Thu Jan 02 22:52:52 EST 2025
Thu Apr 24 23:07:04 EDT 2025
Tue Jul 01 02:59:39 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords FSCN1
Pseudopodia
Metastasis
Prostate cancer
SYTL2
Language English
License 2023. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c564t-f5bbd3d55d6585d60007b8d31c8869afe3f655e55cc3a936e76f11fafc56cb4c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-2013-073X
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12967-023-04146-y
PMID 37147713
PQID 2815662256
PQPubID 43076
PageCount 15
ParticipantIDs doaj_primary_oai_doaj_org_article_f9fd642c0fc14f4cb398c9b7873dac18
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10161564
proquest_miscellaneous_2810917692
proquest_journals_2815662256
gale_infotracmisc_A748284099
gale_infotracacademiconefile_A748284099
pubmed_primary_37147713
crossref_primary_10_1186_s12967_023_04146_y
crossref_citationtrail_10_1186_s12967_023_04146_y
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-05-05
PublicationDateYYYYMMDD 2023-05-05
PublicationDate_xml – month: 05
  year: 2023
  text: 2023-05-05
  day: 05
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Journal of translational medicine
PublicationTitleAlternate J Transl Med
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References O Holt (4146_CR19) 2008; 9
Z Li (4146_CR33) 2022; 33
R Jaiswal (4146_CR40) 2013; 23
X Guan (4146_CR8) 2015; 5
L Hao (4146_CR34) 2021; 54
L Wan (4146_CR35) 2013; 19
JA Joyce (4146_CR5) 2009; 9
M Yu (4146_CR24) 2007; 18
4146_CR31
AW Lambert (4146_CR4) 2017; 168
B Holmberg (4146_CR36) 1962; 195
S Wilkinson (4146_CR7) 2020; 11
Y Dou (4146_CR20) 2012; 22
L Hao (4146_CR14) 2021; 54
4146_CR37
HY Sung (4146_CR25) 2016; 36
M Fukuda (4146_CR17) 2001; 281
LMG Chavas (4146_CR18) 2008; 16
Y Tang (4146_CR38) 2018; 17
DF Quail (4146_CR6) 2013; 19
T Yasuda (4146_CR43) 2012; 23
J Li (4146_CR28) 2020; 580
H Satake (4146_CR26) 2010; 23
T Willmer (4146_CR41) 2013; 328
M Huang (4146_CR32) 2022; 42
W Ma (4146_CR23) 2018; 8
M Ruscetti (4146_CR27) 2016; 35
M Ito (4146_CR16) 2009; 32
B Aikemu (4146_CR39) 2021; 17
W Mei (4146_CR12) 2019; 11
X Li (4146_CR3) 2019; 110
Z Li (4146_CR29) 2020; 10
T Yasuda (4146_CR42) 2015; 460
S Choi (4146_CR11) 2018; 8
Q Liang (4146_CR15) 2021; 42
T Yasuda (4146_CR22) 2014; 127
CR Francis (4146_CR21) 2021; 41
C Xia (4146_CR2) 2022; 135
G Gundem (4146_CR10) 2015; 520
SS Yadav (4146_CR9) 2018; 36
RL Siegel (4146_CR1) 2022; 72
K Yamamoto (4146_CR13) 2013; 29
K Li (4146_CR30) 2019; 11
References_xml – volume: 135
  start-page: 584
  issue: 5
  year: 2022
  ident: 4146_CR2
  publication-title: Chin Med J (Engl)
  doi: 10.1097/CM9.0000000000002108
– volume: 19
  start-page: 1423
  issue: 11
  year: 2013
  ident: 4146_CR6
  publication-title: Nat Med
  doi: 10.1038/nm.3394
– volume: 19
  start-page: 1450
  issue: 11
  year: 2013
  ident: 4146_CR35
  publication-title: Nat Med
  doi: 10.1038/nm.3391
– volume: 10
  issue: 6
  year: 2020
  ident: 4146_CR29
  publication-title: Clin Transl Med
  doi: 10.1002/ctm2.191
– volume: 110
  start-page: 1883
  issue: 6
  year: 2019
  ident: 4146_CR3
  publication-title: Cancer Sci
  doi: 10.1111/cas.14014
– volume: 328
  start-page: 252
  issue: 2
  year: 2013
  ident: 4146_CR41
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2012.09.021
– volume: 17
  start-page: 1716
  issue: 7
  year: 2021
  ident: 4146_CR39
  publication-title: Int J Biol Sci
  doi: 10.7150/ijbs.56694
– volume: 168
  start-page: 670
  issue: 4
  year: 2017
  ident: 4146_CR4
  publication-title: Cell
  doi: 10.1016/j.cell.2016.11.037
– volume: 11
  start-page: 837
  issue: 1
  year: 2020
  ident: 4146_CR7
  publication-title: Nat Commun
  doi: 10.1038/s41467-020-14657-7
– volume: 16
  start-page: 1468
  issue: 10
  year: 2008
  ident: 4146_CR18
  publication-title: Structure
  doi: 10.1016/j.str.2008.07.015
– volume: 54
  issue: 3
  year: 2021
  ident: 4146_CR34
  publication-title: Cell Prolif
  doi: 10.1111/cpr.12994
– volume: 23
  start-page: 11
  issue: 1
  year: 2010
  ident: 4146_CR26
  publication-title: Oncol Rep
– volume: 8
  start-page: 5744
  issue: 20
  year: 2018
  ident: 4146_CR23
  publication-title: Theranostics
  doi: 10.7150/thno.28898
– volume: 127
  start-page: 557
  issue: Pt 3
  year: 2014
  ident: 4146_CR22
  publication-title: J Cell Sci
– volume: 41
  start-page: 1972
  issue: 6
  year: 2021
  ident: 4146_CR21
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/ATVBAHA.121.316113
– volume: 8
  start-page: 5858
  issue: 1
  year: 2018
  ident: 4146_CR11
  publication-title: Sci Rep
  doi: 10.1038/s41598-018-24256-8
– volume: 11
  start-page: 434
  issue: 4
  year: 2019
  ident: 4146_CR12
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers11040434
– volume: 23
  start-page: 1373
  issue: 14
  year: 2013
  ident: 4146_CR40
  publication-title: Curr Biol
  doi: 10.1016/j.cub.2013.06.013
– ident: 4146_CR37
  doi: 10.1083/jcb.202006196
– volume: 36
  start-page: 349
  issue: 8
  year: 2018
  ident: 4146_CR9
  publication-title: Urol Oncol Semin Origin Investig
  doi: 10.1016/j.urolonc.2018.05.008
– volume: 29
  start-page: 1073
  issue: 3
  year: 2013
  ident: 4146_CR13
  publication-title: Oncol Rep
  doi: 10.3892/or.2012.2191
– volume: 32
  start-page: 1101
  issue: 6
  year: 2009
  ident: 4146_CR16
  publication-title: Biol Pharm Bull
  doi: 10.1248/bpb.32.1101
– volume: 18
  start-page: 688
  issue: 2
  year: 2007
  ident: 4146_CR24
  publication-title: Mol Biol Cell
  doi: 10.1091/mbc.e06-10-0914
– volume: 520
  start-page: 353
  issue: 7547
  year: 2015
  ident: 4146_CR10
  publication-title: Nature
  doi: 10.1038/nature14347
– volume: 195
  start-page: 45
  year: 1962
  ident: 4146_CR36
  publication-title: Nature
  doi: 10.1038/195045a0
– volume: 281
  start-page: 1226
  issue: 5
  year: 2001
  ident: 4146_CR17
  publication-title: Biochem Biophys Res Commun
  doi: 10.1006/bbrc.2001.4512
– volume: 33
  start-page: 2496
  issue: 5
  year: 2022
  ident: 4146_CR33
  publication-title: Chin Chem Lett
  doi: 10.1016/j.cclet.2021.11.078
– volume: 9
  start-page: 239
  issue: 4
  year: 2009
  ident: 4146_CR5
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2618
– volume: 9
  start-page: 446
  issue: 4
  year: 2008
  ident: 4146_CR19
  publication-title: Traffic (Copenhagen, Denmark)
  doi: 10.1111/j.1600-0854.2008.00714.x
– volume: 17
  start-page: 77
  issue: 1
  year: 2018
  ident: 4146_CR38
  publication-title: Mol Cancer
  doi: 10.1186/s12943-018-0825-x
– volume: 460
  start-page: 896
  issue: 4
  year: 2015
  ident: 4146_CR42
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2015.03.099
– volume: 72
  start-page: 7
  issue: 1
  year: 2022
  ident: 4146_CR1
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21708
– volume: 580
  start-page: 93
  issue: 7801
  year: 2020
  ident: 4146_CR28
  publication-title: Nature
  doi: 10.1038/s41586-020-2135-x
– volume: 11
  start-page: 3125
  issue: 24
  year: 2019
  ident: 4146_CR30
  publication-title: Future Med Chem
  doi: 10.4155/fmc-2019-0223
– volume: 54
  start-page: e12994
  issue: 3
  year: 2021
  ident: 4146_CR14
  publication-title: Cell Prolif
  doi: 10.1111/cpr.12994
– volume: 42
  start-page: 115
  issue: 1
  year: 2021
  ident: 4146_CR15
  publication-title: Acta Pharmacol Sin
  doi: 10.1038/s41401-020-0399-1
– volume: 23
  start-page: 3229
  issue: 16
  year: 2012
  ident: 4146_CR43
  publication-title: Mol Biol Cell
  doi: 10.1091/mbc.e12-02-0104
– volume: 36
  start-page: 535
  issue: 1
  year: 2016
  ident: 4146_CR25
  publication-title: Oncol Rep
  doi: 10.3892/or.2016.4835
– volume: 35
  start-page: 3781
  issue: 29
  year: 2016
  ident: 4146_CR27
  publication-title: Oncogene
  doi: 10.1038/onc.2015.444
– volume: 22
  start-page: 1022
  issue: 6
  year: 2012
  ident: 4146_CR20
  publication-title: Cell Res
  doi: 10.1038/cr.2012.10
– volume: 5
  start-page: 402
  issue: 5
  year: 2015
  ident: 4146_CR8
  publication-title: Acta Pharmaceutica Sinica B
  doi: 10.1016/j.apsb.2015.07.005
– ident: 4146_CR31
  doi: 10.21203/rs.3.rs-1800606/v1
– volume: 42
  start-page: 447
  issue: 5
  year: 2022
  ident: 4146_CR32
  publication-title: Cancer Commun (Lond)
  doi: 10.1002/cac2.12284
SSID ssj0024549
Score 2.408821
Snippet Metastatic prostate cancer (mPCa) has a poor prognosis with limited treatment options. The high mobility of tumor cells is the key driving characteristic of...
Background Metastatic prostate cancer (mPCa) has a poor prognosis with limited treatment options. The high mobility of tumor cells is the key driving...
BackgroundMetastatic prostate cancer (mPCa) has a poor prognosis with limited treatment options. The high mobility of tumor cells is the key driving...
Abstract Background Metastatic prostate cancer (mPCa) has a poor prognosis with limited treatment options. The high mobility of tumor cells is the key driving...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 303
SubjectTerms Actin
Antibodies
Carrier Proteins - genetics
Cell culture
Cell Line, Tumor
Cell Movement - genetics
Cytoskeleton
Data analysis
Diagnosis
FSCN1
Genomes
Health aspects
Humans
Lymph nodes
Lymphatic Metastasis
Male
Medical prognosis
Membrane Proteins - genetics
Metastases
Metastasis
Microfilament Proteins - genetics
MicroRNAs - genetics
Mobility
Paraffin
Prognosis
Prostate cancer
Prostatic Neoplasms - genetics
Prostatic Neoplasms - pathology
Proteasomes
Protein binding
Proteins
Pseudopodia
Pseudopodia - metabolism
Risk factors
Survival analysis
Synaptotagmin
SYTL2
Transcriptomes
Tumor cells
SummonAdditionalLinks – databaseName: DOAJ (Directory of Open Access Journals)
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxQxEA_SB_FFrJ-rVSIIPkjoZfOxm8daPIpoX9pCfQr5tAe6e3bvCvffO8l-cIugL8KxcJsENpnJzG92Z35B6F00ntvABRGiNoT7qIhaeEFKW1sBBlOYmBNkz-XZFf98La73jvpKOWE9PXC_cMdRRQ8Y2S2iozxyZ5mqnbKgZ8wbR3OZL_i8MZgaWfYg7BlLZGp53IFXA4MA_oksONgGspu5oczW_6dN3nNK84TJPQ-0fIQeDtARn_SPfIjuheYxuv91-Dj-BP26-Hb5pcTrnGAXOvwzbAxgv27V4Tam27l4CLsk51uc3th32O5waG4S50bzHS8vTs8pybUkgEPxugtb365b-IunGkdsGo9XzZ1Jb9meoqvlp8vTMzKcqECckHxDorDWMy-EB-ABl4QQbO0ZdXUtlYmBRSlEEMI5ZhSToZKR0mgiDHeWO_YMHTRtE14gzCUFwQBc44wDpIogD6moqKI31PuqLBAdF1i7gW48nXrxQ-ewo5a6F4oGoegsFL0r0IdpzLon2_hr749JblPPRJSdb4D66EF99L_Up0Dvk9R12s7weM4MVQkwyUSMpU8qDjEpBMGqQEeznrAN3bx51Bs9mIFOl4mLR4LJlAV6OzWnkSm1rQntNvcB_a2kgiV73qvZNKVEp1hVlBWoningbM7zlmZ1k0nCacbykr_8H6v0Cj0o8-YR8DtCB5vbbXgNYGxj3-R99xsgrjKI
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ba9swFBZbB2MvY_e564YGgz0M0ci6WH4aXVkoY-tLW8iehK5tYLPdOCnk3-9IcdKaQcEEbElB8rnL53xC6FM0ntvABRFCGcJ9rEk98YKUVlkBClOYmBNkT-XJBf8xE7Nhw60f0iq3OjErat-6tEd-WCZYEwncJ7921ySdGpW-rg5HaDxEjxJ0WeLqanYbcHEIfraFMkoe9mDbQC2AlSITDhqCrEfGKGP2_6-Z75imcdrkHTs0fYaeDg4kPtpQ_Dl6EJoX6PGv4RP5S3R99vv8Z4m7nGYXevw3LA14gP28x21Mj3MJEXaJ2guc9u17bNc4NFcJeaO5xNOz41NKckUJeKO468PKt10Lt3hX6YhN4_G8uTFpr-0Vuph-Pz8-IcO5CsQJyZckCms980J4cD_gJ_kJVnlGnVKyNjGwKIUIQjjHTM1kqGSkNJoIw53ljr1Ge03bhLcIc0kj_AsEVYyDYxVVxWRNRRW9od5XZYHo9gVrN4COp7Mv_ugcfCipN0TRQBSdiaLXBfqyG9NtIDfu7f0t0W3XM8Fl5wft4lIP0qdjDbPkpZtER3nkzrJaudqCsmLeOKoK9DlRXSehhuk5M9QmwCITPJY-qjhEphAK1wU6GPUEYXTj5i3f6EEZ9PqWdQv0cdecRqYEtya0q9wHPLdK1vDK3mzYbLekBKpYVZQVSI0YcLTmcUszv8pQ4TR79JLv3z-vd-hJmcVCwHWA9paLVXgPztbSfsgS9Q9jTikY
  priority: 102
  providerName: ProQuest
Title SYTL2 promotes metastasis of prostate cancer cells by enhancing FSCN1-mediated pseudopodia formation and invasion
URI https://www.ncbi.nlm.nih.gov/pubmed/37147713
https://www.proquest.com/docview/2815662256
https://www.proquest.com/docview/2810917692
https://pubmed.ncbi.nlm.nih.gov/PMC10161564
https://doaj.org/article/f9fd642c0fc14f4cb398c9b7873dac18
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ba9swFBa9wNjL2L3euqDBYA_DW2Tr5ocxmtJQxhpG20C2FyHr0gY6O43Tsfz7HSlOVrNSMAZbkpF0bt-RdY4Qeue1paWjLGVM6pRaX6RF37I0K2XJQGEy7eMG2RE_HtOvEzbZQuvjjtoJbO507cJ5UuP51cc_18svIPCfo8BL_qkBmwXiDtYn7VOQ_HS5jXbBMolwosEJlf9y77EIhwkVRcpADayDaO78RsdQxXz-_2vtW2aru6Xylo0aPkaPWnCJD1bc8ARtueopenDS_j5_hq7Pfpx_y_AsbsFzDf7lFhrQYTNtcO3D6xhehE3ghDkOa_oNLpfYVZchK0d1gYdnhyOSxmgTQKp41rgbW89qeMSbKEisK4un1W8d1uGeo_Hw6PzwOG3PXEgN43SRelaWNreMWYAmcAsYopQ2J0ZKXmjvcs8Zc4wZk-si505wT4jXHpqbkpr8Bdqp6srtIUw58fAVcLhyCqDLS5HzgjDhrSbWiixBZD3ByrQJycO5GFcqOiaSqxVRFBBFRaKoZYI-bNrMVuk47q09CHTb1AyptOOLen6hWslUvoBe0sz0vSHUU1PmhTRFCYost9oQmaD3geoqsCB0z-g2bgEGGVJnqQNBwWsFN7lI0H6nJgiq6Rav-Uat-VxlIVsPB6XKE_R2Uxxahs1vlatvYh1AdYIXMGUvV2y2GVJIuCgEyRMkOwzYGXO3pJpexjTiJKJ9Tl_d3-3X6GEWxYLBtY92FvMb9waA2KLsoW0xET20OzgafT_txeWMXpQ4uJ8Ofv4F25Iyug
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR1Lb9Mw2BpDAi6IN4EBRgJxQNHqxHaSA0JjUHWs62WdVE6en1slSLqmBfVP8Rv57CbdIqTdJkWREtuR7e8dfw-E3jlpqLKUxYzlMqbGFXHRMyxOVK4YMEwmXXCQHfHBCf0-YZMt9LeNhfFulS1PDIzaVNr_I99NfFoTDtjHP88uYl81yp-utiU01mhxaFd_wGSrPx18Bfi-T5L-t_H-IG6qCsSacbqIHVPKpIYxA8IXbl5KqtykROc5L6SzqeOMWca0TmWRcptxR4iTDoZrRXUK372FboPg7XljL5tcGngUjK02MCfnuzXIUmBDIBXjHgWOFK86wi_UCPhfElwRhV03zStyr_8A3W8UVry3xrCHaMuWj9Cdo-ZI_jG6OP4xHiZ4Ftz6bI1_2YUEjbOe1rhy_nUIWcLaY9cc-3OCGqsVtuW5z_RRnuH-8f6IxCGCBbRfPKvt0lSzCh7xJrISy9Lgaflb-n97T9DJjez4U7RdVqV9jjDlxMFXwIhLKShyLs9SXhCWOSOJMVkSIdJusNBNknNfa-OnCMZOzsUaKAKAIgJQxCpCHzdjZusUH9f2_uLhtunp03OHF9X8TDTULlwBs6SJ7jlNqKNapUWuCwXMMTVSkzxCHzzUhWciMD0tm1gIWKRPxyX2MgqWMJjeRYR2Oj2B-HW3ucUb0TCfWlySSoTebpr9SO9QV9pqGfqAppjxArbs2RrNNkvySRyzjKQRyjsI2Flzt6WcnofU5CRYEJy-uH5eb9DdwfhoKIYHo8OX6F4SSITBtYO2F_OlfQWK3kK9DtSF0elNk_M_eJNm_w
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=SYTL2+promotes+metastasis+of+prostate+cancer+cells+by+enhancing+FSCN1-mediated+pseudopodia+formation+and+invasion&rft.jtitle=Journal+of+translational+medicine&rft.au=Li%2C+Zean&rft.au=Tao%2C+Yiran&rft.au=Gao%2C+Ze&rft.au=Peng%2C+Shirong&rft.date=2023-05-05&rft.pub=BioMed+Central+Ltd&rft.issn=1479-5876&rft.eissn=1479-5876&rft.volume=21&rft.issue=1&rft_id=info:doi/10.1186%2Fs12967-023-04146-y&rft.externalDocID=A748284099
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon